Format

Send to

Choose Destination
Trends Pharmacol Sci. 2011 Jul;32(7):420-34. doi: 10.1016/j.tips.2011.03.006. Epub 2011 Apr 13.

The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium.

Author information

1
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. mghasem2@jhmi.edu

Abstract

Although lithium has largely met its initial promise as the first drug discovered in the modern era of psychopharmacology, to date no definitive mechanism for its effects has been established. It has been proposed that lithium exerts its therapeutic effects by interfering with signal transduction through G-protein-coupled receptor (GPCR) pathways or direct inhibition of specific targets in signaling systems, including inositol monophosphatase and glycogen synthase kinase-3 (GSK-3). Recently, increasing evidence has suggested that N-methyl-D-aspartate receptor (NMDAR)/nitric oxide (NO) signaling could mediate some lithium-induced responses in the brain and peripheral tissues. However, the probable role of the NMDAR/NO system in the action of lithium has not been fully elucidated. In this review, we discuss biochemical, preclinical/behavioral and physiological evidence that implicates NMDAR/NO signaling in the therapeutic effect of lithium. NMDAR/NO signaling could also explain some of side effects of lithium.

PMID:
21492946
DOI:
10.1016/j.tips.2011.03.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center